![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CCL25 |
Gene summary for CCL25 |
![]() |
Gene information | Species | Human | Gene symbol | CCL25 | Gene ID | 6370 |
Gene name | C-C motif chemokine ligand 25 | |
Gene Alias | Ck beta-15 | |
Cytomap | 19p13.2 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | O15444 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6370 | CCL25 | Pat01-B | Human | Stomach | GC | 2.03e-18 | 4.61e-01 | 0.5754 |
6370 | CCL25 | Pat03-B | Human | Stomach | GC | 7.83e-16 | 3.83e-01 | 0.3693 |
6370 | CCL25 | Pat17-B | Human | Stomach | GC | 1.87e-04 | 1.89e-01 | 0.3109 |
6370 | CCL25 | SIM_1 | Human | Stomach | SIM | 3.11e-14 | 4.80e-01 | 0.3573 |
6370 | CCL25 | SIM_4 | Human | Stomach | SIM | 4.19e-06 | 2.99e-01 | 0.2664 |
6370 | CCL25 | EGC | Human | Stomach | GC | 3.97e-04 | 2.06e-01 | 0.1683 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00457856 | Stomach | GC | positive regulation of cell adhesion | 56/1159 | 437/18723 | 1.79e-07 | 1.02e-05 | 56 |
GO:00224076 | Stomach | GC | regulation of cell-cell adhesion | 55/1159 | 448/18723 | 9.21e-07 | 4.39e-05 | 55 |
GO:0071356 | Stomach | GC | cellular response to tumor necrosis factor | 34/1159 | 229/18723 | 1.85e-06 | 8.24e-05 | 34 |
GO:0034612 | Stomach | GC | response to tumor necrosis factor | 35/1159 | 253/18723 | 6.68e-06 | 2.54e-04 | 35 |
GO:0071621 | Stomach | GC | granulocyte chemotaxis | 22/1159 | 125/18723 | 7.88e-06 | 2.80e-04 | 22 |
GO:0007159 | Stomach | GC | leukocyte cell-cell adhesion | 45/1159 | 371/18723 | 1.21e-05 | 3.99e-04 | 45 |
GO:0030595 | Stomach | GC | leukocyte chemotaxis | 32/1159 | 230/18723 | 1.45e-05 | 4.68e-04 | 32 |
GO:0050900 | Stomach | GC | leukocyte migration | 44/1159 | 369/18723 | 2.30e-05 | 6.81e-04 | 44 |
GO:0097530 | Stomach | GC | granulocyte migration | 23/1159 | 148/18723 | 3.99e-05 | 1.00e-03 | 23 |
GO:1903037 | Stomach | GC | regulation of leukocyte cell-cell adhesion | 40/1159 | 336/18723 | 5.53e-05 | 1.30e-03 | 40 |
GO:0030593 | Stomach | GC | neutrophil chemotaxis | 18/1159 | 103/18723 | 5.67e-05 | 1.31e-03 | 18 |
GO:0097529 | Stomach | GC | myeloid leukocyte migration | 29/1159 | 220/18723 | 9.69e-05 | 1.97e-03 | 29 |
GO:0002685 | Stomach | GC | regulation of leukocyte migration | 28/1159 | 210/18723 | 1.04e-04 | 2.05e-03 | 28 |
GO:0002683 | Stomach | GC | negative regulation of immune system process | 47/1159 | 434/18723 | 1.36e-04 | 2.52e-03 | 47 |
GO:1990266 | Stomach | GC | neutrophil migration | 19/1159 | 122/18723 | 1.77e-04 | 3.08e-03 | 19 |
GO:00108106 | Stomach | GC | regulation of cell-substrate adhesion | 28/1159 | 221/18723 | 2.49e-04 | 4.17e-03 | 28 |
GO:00315895 | Stomach | GC | cell-substrate adhesion | 40/1159 | 363/18723 | 2.91e-04 | 4.68e-03 | 40 |
GO:0060326 | Stomach | GC | cell chemotaxis | 35/1159 | 310/18723 | 4.34e-04 | 6.46e-03 | 35 |
GO:00108116 | Stomach | GC | positive regulation of cell-substrate adhesion | 18/1159 | 123/18723 | 5.62e-04 | 7.81e-03 | 18 |
GO:0071674 | Stomach | GC | mononuclear cell migration | 24/1159 | 196/18723 | 1.08e-03 | 1.27e-02 | 24 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CCL25 | SNV | Missense_Mutation | rs541796418 | c.278N>A | p.Arg93Gln | p.R93Q | O15444 | protein_coding | tolerated(0.11) | benign(0.154) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
CCL25 | SNV | Missense_Mutation | novel | c.373N>G | p.Ser125Ala | p.S125A | O15444 | protein_coding | tolerated(0.34) | benign(0) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CCL25 | SNV | Missense_Mutation | c.17T>A | p.Leu6Gln | p.L6Q | O15444 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-CC-A7IH-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
CCL25 | SNV | Missense_Mutation | c.269N>A | p.Leu90Gln | p.L90Q | O15444 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-35-5375-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
CCL25 | SNV | Missense_Mutation | novel | c.261G>T | p.Met87Ile | p.M87I | O15444 | protein_coding | tolerated(0.09) | benign(0.07) | TCGA-95-A4VN-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CCL25 | SNV | Missense_Mutation | novel | c.411N>C | p.Lys137Asn | p.K137N | O15444 | protein_coding | tolerated(0.1) | benign(0.001) | TCGA-CN-6021-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
CCL25 | SNV | Missense_Mutation | novel | c.345G>C | p.Lys115Asn | p.K115N | O15444 | protein_coding | tolerated(0.22) | benign(0.036) | TCGA-CV-7255-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
CCL25 | SNV | Missense_Mutation | novel | c.437N>G | p.Ala146Gly | p.A146G | O15444 | protein_coding | deleterious(0.01) | benign(0.014) | TCGA-D6-A6EN-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
CCL25 | SNV | Missense_Mutation | novel | c.170G>T | p.Ser57Ile | p.S57I | O15444 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-MT-A51X-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CCL25 | SNV | Missense_Mutation | c.230N>T | p.Asn77Ile | p.N77I | O15444 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6370 | CCL25 | HORMONE ACTIVITY, DRUGGABLE GENOME | TNF-ALPHA | 15492285 |
Page: 1 |